Strategic Acquisition Growth Medivation's history of high-profile acquisitions, including its merger with Pfizer and previous interest from Sanofi, indicates a strong market presence and ongoing growth trajectory, presenting opportunities to offer complementary biotechnology and pharmaceutical services or products that support M&A activities.

Focused Oncology Portfolio With a pipeline centered around cancer treatments like Xtandi and MDV3100, Medivation targets a significant and growing segment of the pharmaceutical industry, creating potential sales opportunities in oncology research tools, specialized medical devices, and supportive care solutions.

Regulatory and Compliance Expertise Given recent legal issues related to insider trading investigations involving former executives, there is an open opportunity to provide compliance, legal consulting, or risk management solutions tailored to pharmaceutical companies aiming to strengthen regulatory adherence.

Industry Collaboration Potential Having established licensing and partnership agreements with Astellas, Medivation is positioned as a collaborative partner in drug development; there is an opportunity to offer partnership facilitation, joint R&D solutions, or licensing platforms to accelerate product pipelines.